High body mass index is not associated with increased treatment failure in infliximab treated pediatric patients with inflammatory bowel disease.

Notably, for patients with LOR, dose optimization occurred more frequently in children with a normal BMI at infliximab initiation but had an elevated BMI at last follow up and in those who had an elevated BMI before infliximab initiation and at last follow up (75 and 100%, respectively) compared to children with a normal BMI throughout the study (34.5%), although the numbers were small, and these differences did not reach statistical significance (Table 2 , P = 0.16).

also in 111,027 other papers

When the cohort was further subdivided into those patients whose BMI increased from the normal to elevated range, the average mg per kg dose and infusion number per year were numerically higher at 7.9 mg/kg and 9.3 infusion/year compared to 6.7 mg/kg and 8.0 infusion/year for those with normal BMI throughout, respectively, although this failed to reach statistical significance ( P = 0.82 and P = 0.91, Table 1 b).

also in 6,035 other papers